Cancer News and Research

Latest Cancer News and Research

Tumor microenvironment drives drug resistance in lung cancer subtypes

A study by the University of Barcelona has discovered why the two main types of lung cancer — adenocarcinoma of the lung and squamous cell carcinoma — respond differently to anti-angiogenic therapy, that is, drugs that block the formation of new blood vessels that tumors need in order to grow.

15 Jun 2026

Massive study maps national medicine trends and health inequalities

The team from the BHF Data Science Centre at Health Data Research UK and the University of Liverpool say this type of analysis can offer opportunities for smarter and safer prescribing in their study published in the journal Nature Health.

15 Jun 2026

Dual-target CAR T therapy triggers broad immune response in brain cancer

Dual-target CAR T cell therapy for recurrent glioblastoma (GBM), delivered directly into the cerebrospinal fluid (CSF), triggers a broad immune response, with natural killer (NK) cell activation linked to better patient outcomes and longer overall survival.

15 Jun 2026

Targeted reminders increase serious illness conversations in cancer care

New research in the June 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that small, targeted prompts delivered to both patients and providers at the right moment can significantly increase the number of serious illness conversations that take place.

15 Jun 2026

Light-controlled molecular switch wakes lung cancer cells for treatment

Researchers from ETH Zurich have developed a molecular switch that is controlled by light. It wakes lung cancer cells up from a protective dormant state so that they are more accessible for treatment.

15 Jun 2026

Novel analysis identifies unique proliferation gene alterations in diverse cancer patients

New research to be presented today (Monday) at the annual conference of the European Society of Human Genetics shows that a cancer patient's genetic ancestry can have a significant effect both on how their disease progresses and their survival. In the largest study of its kind, researchers examined nearly 1,900 specific genetic changes in tumors in order to measure whether certain mutations were more common in patients with different historic geographic origins.

15 Jun 2026

Longer hormone exposure may increase thyroid cancer risk in women

Longer lifetime exposure to female hormones may increase the risk of thyroid cancer in women, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

Study finds gaps in guideline-based testosterone prescribing practices

Only a small number of men who were prescribed testosterone therapy received appropriate, guideline-concordant diagnostic testing, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill, by Sophia Sinha, M.D., clinical assistant professor at the University of Michigan in Ann Arbor, Mich.

14 Jun 2026

Researchers identify vulnerabilities shared by surviving cancer cells

Cancer drugs can shrink fast-growing tumors. But sometimes a few tumor cells survive. These "persister" cells seed new tumors, forcing cancer patients into arduous cycles of testing and treatment.

12 Jun 2026

FDA approves new adjuvant treatment option for ccRCC patients with recurrence risk

The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2α inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions.

12 Jun 2026

Renowned physician‑scientist to lead Houston Methodist's cell and gene therapy research

Malcolm Brenner, an internationally recognized physician‑scientist renowned for his leadership in cell and gene therapy, has been tapped to lead the newly formed Houston Methodist Center for Cell and Gene Therapy.

12 Jun 2026

Major NIH grant helps establish the Oklahoma Center of ImmunoEngineering

The University of Oklahoma has received an $11.5 million award from the National Institutes of Health to establish the Oklahoma Center of ImmunoEngineering, a new research center designed to accelerate the study and treatment of diseases rooted in the immune system.

12 Jun 2026

Cellular process discovery may lead to new cancer treatments

A molecular geneticist at Montana State University has discovered a cellular process once believed impossible by scientists – the creation of the amino acid cysteine within a living cell when the cell's primary systems to do so fail. The discovery may one day lead to new cancer treatments.

12 Jun 2026

Novel metal-free prodrug suppresses cancer spread in preclinical models

A carefully designed metal-free carbon monoxide prodrug may help prevent some of the deadliest forms of cancer from spreading, according to researchers at Weill Cornell Medicine.

12 Jun 2026

New poll reveals political divide over public water fluoridation

As the debate over the value of adding fluoride to public drinking water percolates in communities across the nation, a new nationally representative survey from the Annenberg Public Policy Center (APPC) of the University of Pennsylvania finds Americans sharply divided over the use of fluoride in public drinking water.

12 Jun 2026

New genetic driver found for rare small intestinal cancers

A signaling system known as the Wnt pathway plays a central role in how cells in the intestine grow, divide, and renew themselves.

12 Jun 2026

Review outlines virtual tumor concept and next-generation immunotherapy

A comprehensive review led by Associate Researcher Linnan Zhu and Academician Zemin Zhang at Biomedical Pioneering Innovation Center (BIOPIC), Peking University, China, and Chongqing Medical University, China, was published in Volume 2, article number 27 of the journal Immunity & Inflammation on June 05, 2026.

12 Jun 2026

PhoreMost announces lead oncology program and appoints Chief Medical Officer to support clinical entry

PhoreMost Limited, a biotech company focused on turning scientific breakthroughs into life-changing cancer drugs, today announced its lead program, PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers.

From PhoreMost 12 Jun 2026

New combination therapy improves outcomes in high-risk leukemia

A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has developed a novel combination therapy that significantly improves treatment outcomes and survival in patients with acute myeloid leukaemia (AML) with FLT3 gene mutations.

11 Jun 2026

Scientists uncover protein-folding mechanism linked to diabetes progression

Origami masters turn simple sheets of paper into ornate sculptures. In the origami of life, our cells must fold proteins into specific three-dimensional shapes before they can carry out their biological jobs.

11 Jun 2026